Compare PulteGroup, Inc. (PHM) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PulteGroup, Inc. vs Summit Therapeutics Inc — how do they compare? PulteGroup, Inc. trades at $111.39 (market cap $21.63B), while Summit Therapeutics Inc trades at $17.32 (market cap $13.71B). The key difference: PulteGroup, Inc. is the larger of the two by market cap, and PulteGroup, Inc. pays a 0.92% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold PulteGroup, Inc. for 91 Days and Summit Therapeutics Inc for 16 Days on average.
| PHM | SMMT | |
|---|---|---|
Market Cap | $21.63B | $13.71B |
Volume | 2,324,729 | 6,173,057 |
Sector | Consumer Cyclical | Health |
52-Week High | $142.56 | $26.38 |
52-Week Low | $110.11 | $12.43 |
Typical Hold Time | 91 Days | 16 Days |
Enterprise Value | $22.04B | $13.04B |
Dividend Yield | 0.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PulteGroup (PHM) trades at $112.33, down 3.25% amid broader housing sector weakness driven by rising mortgage rates. The stock shows bearish technical signals with key support at $110, while fundamentals reveal solid profitability with 11.62% net margin and attractive valuation at P/E of 11.6. Recent earnings show mixed results with Q2 beat but Q4 and Q1 misses, with Q3 results pending. The company maintains strong cash flow generation with $355M net cash flow in 2025.
PHM presents a value opportunity with below-market valuation and consistent profitability, though near-term headwinds from rising rates pressure housing demand. Analyst consensus targets $139.80 (24% upside) with 45% buy ratings, but technical weakness and macroeconomic risks require careful monitoring. The dividend yield provides income support during market volatility.
Summit Therapeutics (SMMT) trades at $17.95, up 3.7% with strong technical momentum and bullish analyst sentiment. The stock shows negative profitability metrics but benefits from AstraZeneca's $2 billion strategic investment and clinical collaborations. Recent news highlights positive clinical trial results for ivonescimab, driving investor optimism despite current financial losses.
The outlook remains speculative with significant upside potential based on analyst consensus targets averaging $29.33, though high valuation multiples and negative cash flows present substantial risk. Success of clinical trials and partnership execution will determine long-term value creation for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
